Featured Research

from universities, journals, and other organizations

Restricted Fetal Growth Increases Risk Of Irritable Bowel Syndrome

Date:
September 29, 2006
Source:
BMJ Specialty Journals
Summary:
Babies weighing less than the standard weight seem to be at significantly greater risk of developing irritable bowel syndrome or IBS, suggests research published ahead of print in the journal Gut. The Norwegian authors base their findings on 3334 twin pairs, 1250 of whom were identical. The twins completed a comprehensive questionnaire about their health, including whether they had ever had IBS.

Babies weighing less than the standard weight seem to be at significantly greater risk of developing irritable bowel syndrome or IBS, suggests research published ahead of print in the journal Gut.

The Norwegian authors base their findings on 3334 twin pairs, 1250 of whom were identical. The twins completed a comprehensive questionnaire about their health, including whether they had ever had IBS.

This information was then matched with weight at birth, supplied by the national twin registry and divided into four groups, ranging from less than 1500 g to more than 2500 g. A healthy birthweight is considered to be above 2500 g.

The rate of IBS across the entire sample was 5.4%, roughly one in 20. But there was a significant gender difference: the rate in men was 3%, while that in women was 7%.

There was little difference, however, in the average age of onset between the two sexes. The first signs of the condition appeared at the age of 18 in men, and a year earlier in women.

Only one in four of those who reported IBS symptoms at some point in their lives, were symptom free at the time of the survey, and the average duration of their symptoms was more than 4.5 years.

The likelihood of IBS was stronger among the identical twins, suggesting that genetic factors do play a part, say the authors.

But the risk of the condition was 2.5 times greater among those whose birthweights were below 1500 g as it was among those weighing more than 2500 g at birth. And it was higher in the lower weight baby of the twin pair.

The age at which symptoms started also seemed to be associated with birthweight. Those weighing in at less than 1500 g at birth were, on average, likely to develop IBS more than 7 years earlier than those weighing over 1500 g.

The authors point out that several chronic diseases have been linked to low birthweight, and that the healthy development of the digestive system, which is not complete at birth, could be hindered by insufficient fetal growth.


Story Source:

The above story is based on materials provided by BMJ Specialty Journals. Note: Materials may be edited for content and length.


Cite This Page:

BMJ Specialty Journals. "Restricted Fetal Growth Increases Risk Of Irritable Bowel Syndrome." ScienceDaily. ScienceDaily, 29 September 2006. <www.sciencedaily.com/releases/2006/09/060927201626.htm>.
BMJ Specialty Journals. (2006, September 29). Restricted Fetal Growth Increases Risk Of Irritable Bowel Syndrome. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/09/060927201626.htm
BMJ Specialty Journals. "Restricted Fetal Growth Increases Risk Of Irritable Bowel Syndrome." ScienceDaily. www.sciencedaily.com/releases/2006/09/060927201626.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins